News & Resources

Featured Stories

GlobeNewswire

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from CIRM to Support Clinical Development of SRN-101 in High-Grade Glioma Read More

Press Releases | Posted on 6.26.26

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from CIRM to Support Clinical Development of SRN-101 in High-Grade Glioma

Press Releases | Posted on 4.24.26

Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026

Press Releases | Posted on 3.23.26

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma

Press Releases | Posted on 2.23.26

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma

Press Releases | Posted on 1.28.26

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage

Press Releases | Posted on 1.7.26

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences

Press Releases | Posted on 5.12.25

Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Press Releases | Posted on 3.4.25

Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders

Press Releases | Posted on 11.18.24

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

Press Releases | Posted on 5.8.24

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

1 2